

## Technology Advisory Committee C Interests Register

**Topic: Molnupiravir for treating COVID-19 [ID6340]**

**Publication Date: 16 April 2025**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	TAC Committee Member	Direct- financial	Michael has participated in an advisory panel for Pfizer in an unrelated disease area, prostate cancer.	11/10/2024 11/02/2025	It was agreed that Michael's declaration would not prevent him from participating in discussions on this appraisal.
Dr Kate Ren	TAC Committee Member	Non-financial	Kate was a member of the EAG which conducted the MTA for Covid-19 treatments. She also provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	12/10/2024 11/02/2025	It was agreed that Kate's declaration would not prevent her from participating in discussions on this appraisal.
Elizabeth Thurgar	TAC Committee Member	Direct- financial	In the past 12 months, Elizabeth has provided consultancy advice to Kite, owned by Gilead Sciences, a listed comparator company, in an unrelated condition: mantle cell lymphoma. Elizabeth currently works	14/10/2024 11/02/2025	It was agreed that Elizabeth's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			with Pfizer, a listed comparator company, in an unrelated indication, non-small cell lung cancer.		
Dr Prithwiraj Das	TAC Committee Member	Non-financial	Prithwiraj, is currently engaged in helping one of the comparator manufacturers, GSK on an unrelated indication.	23/01/2025	
David Lowe	Clinical Expert	Direct- financial	David is a member of the NHS England National Expert Working Group for COVID-19 therapeutics, the Independent Advisory Group on highest risk subgroups for COVID-19 and the European Society for Immunodeficiencies Clinical Working Party COVID-19 group. He was the Chief Investigator of the FLARE trial investigating early oral antivirals for COVID-19 (2020-2021). He is an Investigator, co-applicant and lead for Virology substudies of the PANORAMIC trial investigating early oral antivirals for COVID-19, including molnupiravir. He has published in multiple publications on viral infection and antivirals. His institution, UCL, has received	26/09/2024 11/02/2025	It was agreed that David's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			research grants from GSK, a comparator company. David's spouse is employed by GSK, a comparator company. His nominating organisation, the British Society for Immunology, has received funding from MSD.		
Brendan Payne	Clinical Expert	Direct- financial	Brendan is the principal investigator for a current MSD sponsored clinical trial which is running at his site. It is not in this clinical disease area.	14/06/2024	It was agreed that Brendan's declaration would not prevent him from providing expert advice to the committee.
Robert Burns	Clinical Expert	Direct- financial	Robert holds shares in GSK, a comparator company.	02/10/2024 11/02/2025	It was agreed that Robert's declaration would not prevent him from providing expert advice to the committee.